The promise of pharmacogenetics, the study of the role of inheritancein the individual variation in drug response, lies in its potentialto identify the right drug and dose for each patient. Even thoughindividual differences in drug response can result from theeffects of age, sex, disease, or drug interactions, geneticfactors also influence both the efficacy of a drug and the likelihoodof an adverse reaction.1,2,3 This article briefly reviews conceptsthat underlie the emerging fields of pharmacogenetics and pharmacogenomics,with an emphasis on the pharmacogenetics of drug metabolism.Although only a few examples will be provided to . . . [Full Text of this Article]
Pharmacogenetics of Drug Metabolism
Pharmacogenetics of Phase I Drug Metabolism
Pharmacogenetics of Phase II Drug Metabolism
From Pharmacogenetics to Pharmacogenomics
Conclusions
Source Information
From the Departments of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School, Mayo Clinic, and Mayo Foundation, Rochester, Minn.
Address reprint requests to Dr. Weinshilboum at the Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School–Mayo Clinic–Mayo Foundation, Rochester, MN 55905, or at weinshilboum.richard@mayo.edu.
Related Letters:
Pharmacogenetics
Padrini R., Ferrari M., Carnes M., Noah L., Weinshilboum R., Evans W. E., McLeod H. L., Goldstein D. B., Vallance P.
Extract |
Full Text |
PDF
N Engl J Med 2003;
348:2041-2043, May 15, 2003.
Correspondence
This article has been cited by other articles:
Young, R. P., Hopkins, R., Eaton, T. E.
(2009). Pharmacological actions of statins: potential utility in COPD. ERR
18: 222-232
[Abstract][Full Text]
Jaramillo, K. S., Scruth, E., Cheng, E.
(2009). Prolonged Paralysis and Apnea After Receiving a Neuromuscular Blocking Agent: What Nurses Should Know. Am J Crit Care
18: 592-588
[Abstract][Full Text]
Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., Fritz, P., Simon, W., Suman, V. J., Ames, M. M., Safgren, S. L., Kuffel, M. J., Ulmer, H. U., Bolander, J., Strick, R., Beckmann, M. W., Koelbl, H., Weinshilboum, R. M., Ingle, J. N., Eichelbaum, M., Schwab, M., Brauch, H.
(2009). Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA
302: 1429-1436
[Abstract][Full Text]
Alarcon, R. D.
(2009). Pharmacogenomic perspectives on the management of mood disorders. Psychiatr. Bull.
33: 361-363
[Abstract][Full Text]
Marin, F., Gonzalez-Conejero, R., Capranzano, P., Bass, T. A., Roldan, V., Angiolillo, D. J.
(2009). Pharmacogenetics in cardiovascular antithrombotic therapy.. J Am Coll Cardiol
54: 1041-1057
[Abstract][Full Text]
Ising, M., Lucae, S., Binder, E. B., Bettecken, T., Uhr, M., Ripke, S., Kohli, M. A., Hennings, J. M., Horstmann, S., Kloiber, S., Menke, A., Bondy, B., Rupprecht, R., Domschke, K., Baune, B. T., Arolt, V., Rush, A. J., Holsboer, F., Muller-Myhsok, B.
(2009). A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression. Arch Gen Psychiatry
66: 966-975
[Abstract][Full Text]
Ghofrani, H. A., Barst, R. J., Benza, R. L., Champion, H. C., Fagan, K. A., Grimminger, F., Humbert, M., Simonneau, G., Stewart, D. J., Ventura, C., Rubin, L. J.
(2009). Future perspectives for the treatment of pulmonary arterial hypertension.. J Am Coll Cardiol
54: S108-S117
[Abstract][Full Text]
Wolverton, S. E.
(2009). Optimizing Clinical Use of Azathioprine With Newer Pharmacogenetic Data. Arch Dermatol
145: 707-710
[Full Text]
Ribrag, V., Koscielny, S., Casasnovas, O., Cazeneuve, C., Brice, P., Morschhauser, F., Gabarre, J., Stamatoullas, A., Lenoir, G., Salles, G., on Behalf from the Groupe d'Etude des Lymphomes ag,
(2009). Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood
113: 3307-3313
[Abstract][Full Text]
Gulseth, M. P., Grice, G. R., Dager, W. E.
(2009). Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery. Am J Health Syst Pharm
66: 123-133
[Abstract][Full Text]
Wang, L., Weinshilboum, R. M.
(2008). Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet
17: R174-R179
[Abstract][Full Text]
Leeder, J. S., Pearce, R. E., Gaedigk, A., Modak, A., Rosen, D. I.
(2008). Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype. J Clin Pharmacol
48: 1041-1051
[Abstract][Full Text]
Manamperi, A.
(2008). Current Developments in Genomics and Personalized Health Care: Impact on Public Health. Asia Pac J Public Health
20: 242-250
[Abstract]
Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., Hong, Y.
(2008). Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation
117: 2544-2565
[Abstract][Full Text]
Hayes, D. F., Stearns, V., Rae, J., Flockhart, D., on behalf of the Consortium on Breast Cancer Pharm,
(2008). A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?. JNCI J Natl Cancer Inst
100: 610-613
[Full Text]
Parving, H.-H., de Zeeuw, D., Cooper, M. E., Remuzzi, G., Liu, N., Lunceford, J., Shahinfar, S., Wong, P. H., Lyle, P. A., Rossing, P., Brenner, B. M.
(2008). ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. J. Am. Soc. Nephrol.
19: 771-779
[Abstract][Full Text]
Mrazek, M., Koenig, B., Skime, M., Snyder, K., Hook, C., Black, J. III, Mrazek, D.
(2007). Assessing Attitudes about Genetic Testing as a Component of Continuing Medical Education. Acad. Psychiatry
31: 447-451
[Abstract][Full Text]
Bakker, J. A., Bierau, J., Drent, M.
(2007). Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?. Eur Respir J
30: 821-822
[Full Text]
McAlpine, D. E., O'Kane, D. J., Black, J. L., Mrazek, D. A.
(2007). Cytochrome P450 2D6 Genotype Variation and Venlafaxine Dosage. Mayo Clin Proc.
82: 1065-1068
[Abstract][Full Text]
Daly, T. M., Dumaual, C. M., Miao, X., Farmen, M. W., Njau, R. K., Fu, D.-J., Bauer, N. L., Close, S., Watanabe, N., Bruckner, C., Hardenbol, P., Hockett, R. D.
(2007). Multiplex Assay for Comprehensive Genotyping of Genes Involved in Drug Metabolism, Excretion, and Transport. Clin. Chem.
53: 1222-1230
[Abstract][Full Text]
Wang, Z., Wang, J., Tantoso, E., Wang, B., Tai, A. Y.P., Ooi, L. L.P.J., Chong, S. S., Lee, C. G.L.
(2007). Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. Hum Mol Genet
16: 1367-1380
[Abstract][Full Text]
Hartford, C., Vasquez, E., Schwab, M., Edick, M. J., Rehg, J. E., Grosveld, G., Pui, C.-H., Evans, W. E., Relling, M. V.
(2007). Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. Cancer Res.
67: 4965-4972
[Abstract][Full Text]
Kishi, S., Cheng, C., French, D., Pei, D., Das, S., Cook, E. H., Hijiya, N., Rizzari, C., Rosner, G. L., Frudakis, T., Pui, C.-H., Evans, W. E., Relling, M. V.
(2007). Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood
109: 4151-4157
[Abstract][Full Text]
Polanczyk, G., Zeni, C., Genro, J. P., Guimaraes, A. P., Roman, T., Hutz, M. H., Rohde, L. A.
(2007). Association of the Adrenergic {alpha}2A Receptor Gene With Methylphenidate Improvement of Inattentive Symptoms in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry
64: 218-224
[Abstract][Full Text]
Przekop, P. R. Jr, Tulgan, H., Przekop, A. A., Glantz, M.
(2006). Adverse Drug Reaction to Methotrexate: Pharmacogenetic Origin. JAOA: Journal of the American Osteopathic Association
106: 706-707
[Abstract][Full Text]
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., Ring, H. Z., Shuldiner, A. R., Weinshilboum, R. M., Weiss, S. T., for the Pharmacogenetics Research Network,
(2006). Pharmacogenomics: Challenges and Opportunities.. ANN INTERN MED
145: 749-757
[Abstract][Full Text]
Meletiadis, J., Chanock, S., Walsh, T. J.
(2006). Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. Clin. Microbiol. Rev.
19: 763-787
[Abstract][Full Text]
Gardiner, S. J., Begg, E. J.
(2006). Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacol. Rev.
58: 521-590
[Abstract][Full Text]
Wu, X., Gu, J., Wu, T.-T., Swisher, S. G., Liao, Z., Correa, A. M., Liu, J., Etzel, C. J., Amos, C. I., Huang, M., Chiang, S. S., Milas, L., Hittelman, W. N., Ajani, J. A.
(2006). Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer. JCO
24: 3789-3798
[Abstract][Full Text]
Mrazek, D. A.
(2006). Psychiatric Pharmacogenomics. Focus
4: 339-
[Abstract][Full Text]
Weinshilboum, R., Wang, L.
(2006). Pharmacogenomics: Bench to Bedside. Focus
4: 431-
[Abstract][Full Text]
Ezzeldin, H. H., Diasio, R. B.
(2006). Genetic testing in cancer therapeutics.. Clin. Cancer Res.
12: 4137-4141
[Full Text]
Monzo, M., Brunet, S., Urbano-Ispizua, A., Navarro, A., Perea, G., Esteve, J., Artells, R., Granell, M., Berlanga, J., Ribera, J. M., Bueno, J., Llorente, A., Guardia, R., Tormo, M., Torres, P., Nomdedeu, J. F., Montserrat, E., Sierra, J., for CETLAM,
(2006). Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood
107: 4871-4879
[Abstract][Full Text]
Hull, J. H.K., Toma, T. P., Bhowmik, A., Rajakulasingam, R., Demedts, M., Buhl, R., Costabel, U., the IFIGENIA Study Group,
(2006). Acetylcysteine in Pulmonary Fibrosis. NEJM
354: 1089-1091
[Full Text]
Blum, K., Chen, T. J.H., Blum, S. H., Downs, B. W., Braverman, E. R., Mengucci, J. F., Meshkin, B.
(2006). Nutrigenomics and pharmacogenomics: a scientific wonderland. Social Science Information
45: 35-52
[Abstract]
Padmanabhan, S., Wallace, C., Munroe, P. B., Dobson, R., Brown, M., Samani, N., Clayton, D., Farrall, M., Webster, J., Lathrop, M., Caulfield, M., Dominiczak, A. F., Connell, J. M.
(2006). Chromosome 2p Shows Significant Linkage to Antihypertensive Response in the British Genetics of Hypertension Study. Hypertension
47: 603-608
[Abstract][Full Text]
Navarro, V. J., Senior, J. R.
(2006). Drug-Related Hepatotoxicity. NEJM
354: 731-739
[Full Text]
Relling, M. V., Pui, C.-H., Cheng, C., Evans, W. E.
(2006). Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood
107: 843-844
[Full Text]
Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M., Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M.
(2005). Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation
112: 3654-3666
[Full Text]
Freimuth, R. R., Xiao, M., Marsh, S., Minton, M., Addleman, N., Van Booven, D. J., McLeod, H. L., Kwok, P.-Y.
(2005). Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet
14: 3595-3603
[Abstract][Full Text]
Ohnishi, A., Murakami, S., Akizuki, S., Mochizuki, J., Echizen, H., Takagi, I.
(2005). In Vivo Metabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease. J Clin Pharmacol
45: 1221-1229
[Abstract][Full Text]
Burke, W.
(2005). Contributions of Public Health to Genetics Education for Health Care Professionals. Health Educ Behav
32: 668-675
[Abstract]
Rubinstein, W. S., Roy, H. K.
(2005). Practicing Medicine at the Front Lines of the Genomic Revolution. Arch Intern Med
165: 1815-1817
[Full Text]
Willard, H. F, Angrist, M., Ginsburg, G. S
(2005). Genomic medicine: genetic variation and its impact on the future of health care. Phil Trans R Soc B
360: 1543-1550
[Abstract][Full Text]
Ingelman-Sundberg, M., Rodriguez-Antona, C.
(2005). Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B
360: 1563-1570
[Abstract][Full Text]
Wang, L., Nguyen, T. V., McLaughlin, R. W., Sikkink, L. A., Ramirez-Alvarado, M., Weinshilboum, R. M.
(2005). Human thiopurine S-methyltransferase pharmacogenetics: Variant allozyme misfolding and aggresome formation. Proc. Natl. Acad. Sci. USA
102: 9394-9399
[Abstract][Full Text]
Rocha, J. C. C., Cheng, C., Liu, W., Kishi, S., Das, S., Cook, E. H., Sandlund, J. T., Rubnitz, J., Ribeiro, R., Campana, D., Pui, C.-H., Evans, W. E., Relling, M. V.
(2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood
105: 4752-4758
[Abstract][Full Text]
Lin, M., Wu, R.
(2005). Theoretical Basis for the Identification of Allelic Variants That Encode Drug Efficacy and Toxicity. Genetics
170: 919-928
[Abstract][Full Text]
Wilkinson, G. R.
(2005). Drug Metabolism and Variability among Patients in Drug Response. NEJM
352: 2211-2221
[Full Text]
Johnson, J. A., Cavallari, L. H.
(2005). Cardiovascular pharmacogenomics. Exp Physiol
90: 283-289
[Abstract][Full Text]
Stearns, V., Jin, Y., Desta, Z., Rae, J., Skaar, T., Li, L., Storniolo, A. M., Hayes, D. F., Flockhart, D. A.
(2005). Pharmacogenetics in the Endocrine Treatment of Breast Cancer. aacredbook
2005: 325-330
[Full Text]
Hohaus, S., Di Ruscio, A., Di Febo, A., Massini, G., D'Alo', F., Guidi, F., Mansueto, G., Voso, M. T., Leone, G.
(2005). Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma. Clin. Cancer Res.
11: 2175-2179
[Abstract][Full Text]
Kreiner, T., Buck, K. T.
(2005). Moving toward whole-genome analysis: A technology perspective. Am J Health Syst Pharm
62: 296-305
[Abstract][Full Text]
Kauwell, G. P. A.
(2005). Emerging Concepts in Nutrigenomics: A Preview of What Is to Come. Nutr Clin Pract
20: 75-87
[Abstract][Full Text]
Marin, F., Gonzalez-Conejero, R., Lee, K. W., Corral, J., Roldan, V., Lopez, F., Sogorb, F., Caturla, J., Lip, G. Y.H., Vicente, V.
(2005). A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol
45: 25-29
[Abstract][Full Text]
Chen, Y.-C., Hunter, D. J.
(2005). Molecular Epidemiology of Cancer. CA Cancer J Clin
55: 45-54
[Abstract][Full Text]
Kim, K., Johnson, J. A., Derendorf, H.
(2004). Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. J Clin Pharmacol
44: 1083-1105
[Abstract][Full Text]
Liu, T., Johnson, J. A., Casella, G., Wu, R.
(2004). Sequencing Complex Diseases With HapMap. Genetics
168: 503-511
[Abstract][Full Text]
Brans, R., Laizane, D., Khan, A., Blomeke, B.
(2004). N-Acetyltransferase 2 Genotyping: An Accurate and Feasible Approach for Simultaneous Detection of the Most Common NAT2 Alleles. Clin. Chem.
50: 1264-1266
[Full Text]
Pui, C.-H., Relling, M. V., Downing, J. R.
(2004). Acute Lymphoblastic Leukemia. NEJM
350: 1535-1548
[Full Text]
Murphy, D. L., Lerner, A., Rudnick, G., Lesch, K.-P.
(2004). Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics. Mol. Interv.
4: 109-123
[Abstract][Full Text]
Goetz, M. P., Ames, M. M., Weinshilboum, R. M.
(2004). Primer on Medical Genomics Part XII: Pharmacogenomics--General Principles With Cancer as a Model. Mayo Clin Proc.
79: 376-384
[Abstract]
Reid, J. M., Walker, D. L., Miller, J. K., Benson, L. M., Tomlinson, A. J., Naylor, S., Blajeski, A. L., LoRusso, P. M., Ames, M. M.
(2004). The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes. Clin. Cancer Res.
10: 1471-1480
[Abstract][Full Text]
Jones, R. B.
(2004). Overcoming Methodological Weakness in Dose-Intense Alkylating Agent Studies through Pharmacology. Clin. Cancer Res.
10: 413-414
[Full Text]
Mohrenweiser, H. W.
(2004). Genetic Variation and Exposure Related Risk Estimation: Will Toxicology Enter a New Era? DNA Repair and Cancer as a Paradigm. Toxicol Pathol
32: 136-145
[Abstract]
Burke, W.
(2003). Genomics as a Probe for Disease Biology. NEJM
349: 969-974
[Full Text]
Guttmacher, A. E., Collins, F. S.
(2003). Welcome to the Genomic Era. NEJM
349: 996-998
[Full Text]
Lee, W. M.
(2003). Drug-Induced Hepatotoxicity. NEJM
349: 474-485
[Full Text]
Nabel, E. G.
(2003). Cardiovascular Disease. NEJM
349: 60-72
[Full Text]
Padrini, R., Ferrari, M., Carnes, M., Noah, L., Weinshilboum, R., Evans, W. E., McLeod, H. L., Goldstein, D. B., Vallance, P.
(2003). Pharmacogenetics. NEJM
348: 2041-2043
[Full Text]
Evans, W. E., McLeod, H. L.
(2003). Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects. NEJM
348: 538-549
[Full Text]
Goldstein, D. B.
(2003). Pharmacogenetics in the Laboratory and the Clinic. NEJM
348: 553-556
[Full Text]
Previous
